<div id="readability-page-1"><ul><li>Want Diversified Upside in Biotechnology? Check out LABU</li></ul>Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) - Equities researchers at HC Wainwright cut their Q3 2026 earnings estimates for shares of Arrowhead Pharmaceuticals in a research note issued to investors on Tuesday, May 12th. HC Wainwright analyst P. Trucchio now anticipates that the biotechnology company will post earnings per share of ($1.03) for the quarter, down from their prior estimate of ($1.02). HC Wainwright currently has a &#34;Buy&#34; rating and a $100.00 target price on the stock. The consensus estimate for Arrowhead Pharmaceuticals' current full-year earnings is ($2.98) per share. HC Wainwright also issued estimates for Arrowhead Pharmaceuticals' Q4 2026 earnings at ($0.93) EPS, FY2026 earnings at ($2.68) EPS, Q1 2027 earnings at ($1.04) EPS, Q2 2027 earnings at ($1.25) EPS, Q3 2027 earnings at ($1.26) EPS and FY2027 earnings at ($3.37) EPS.A number of other analysts have also recently commented on the stock. B. Riley Financial lifted their target price on shares of Arrowhead Pharmaceuticals from $61.00 to $101.00 and gave the stock a &#34;buy&#34; rating in a research note on Thursday, January 22nd. Morgan Stanley upgraded shares of Arrowhead Pharmaceuticals from an &#34;equal weight&#34; rating to an &#34;overweight&#34; rating and lifted their target price for the stock from $78.00 to $100.00 in a research note on Tuesday, April 21st. Royal Bank Of Canada lifted their target price on shares of Arrowhead Pharmaceuticals from $80.00 to $87.00 and gave the stock an &#34;outperform&#34; rating in a research note on Friday, May 8th. Sanford C. Bernstein lifted their target price on shares of Arrowhead Pharmaceuticals from $35.00 to $46.00 and gave the stock a &#34;market perform&#34; rating in a research note on Wednesday. Finally, Weiss Ratings reiterated a &#34;hold (c-)&#34; rating on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, May 6th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, Arrowhead Pharmaceuticals currently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $87.80.Read Our Latest Stock Report on Arrowhead Pharmaceuticals<h2>Arrowhead Pharmaceuticals Stock Down 1.5%</h2>NASDAQ:ARWR opened at $77.88 on Thursday. Arrowhead Pharmaceuticals has a fifty-two week low of $14.30 and a fifty-two week high of $80.67. The stock has a market capitalization of $10.97 billion, a P/E ratio of -36.22 and a beta of 1.28. The company has a debt-to-equity ratio of 1.41, a quick ratio of 6.23 and a current ratio of 6.23. The company's 50-day simple moving average is $65.40 and its 200-day simple moving average is $61.45. Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last released its quarterly earnings results on Thursday, May 7th. The biotechnology company reported ($0.93) earnings per share for the quarter, beating analysts' consensus estimates of ($1.10) by $0.17. Arrowhead Pharmaceuticals had a negative net margin of 48.38% and a negative return on equity of 55.09%. The business had revenue of $73.74 million for the quarter, compared to analysts' expectations of $73.84 million. During the same period last year, the business earned $2.75 EPS. The company's revenue was down 86.4% compared to the same quarter last year. <h2>Institutional Trading of Arrowhead Pharmaceuticals</h2>Institutional investors and hedge funds have recently bought and sold shares of the business. M&amp;T Bank Corp increased its holdings in shares of Arrowhead Pharmaceuticals by 2,569.6% during the 4th quarter. M&amp;T Bank Corp now owns 240,634 shares of the biotechnology company's stock valued at $15,976,000 after purchasing an additional 231,620 shares in the last quarter. Nordea Investment Management AB increased its holdings in shares of Arrowhead Pharmaceuticals by 74.5% during the 3rd quarter. Nordea Investment Management AB now owns 372,282 shares of the biotechnology company's stock valued at $12,661,000 after purchasing an additional 158,937 shares in the last quarter. Erste Asset Management GmbH increased its holdings in shares of Arrowhead Pharmaceuticals by 55.3% during the 3rd quarter. Erste Asset Management GmbH now owns 73,000 shares of the biotechnology company's stock valued at $2,466,000 after purchasing an additional 26,000 shares in the last quarter. Vanguard Personalized Indexing Management LLC purchased a new position in shares of Arrowhead Pharmaceuticals during the 3rd quarter valued at approximately $287,000. Finally, Johnson Investment Counsel Inc. purchased a new position in shares of Arrowhead Pharmaceuticals during the 3rd quarter valued at approximately $781,000. 62.61% of the stock is currently owned by institutional investors and hedge funds. <h2>Insider Buying and Selling</h2>In other Arrowhead Pharmaceuticals news, insider James C. Hamilton sold 10,000 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Thursday, April 23rd. The shares were sold at an average price of $75.00, for a total transaction of $750,000.00. Following the completion of the sale, the insider directly owned 226,958 shares in the company, valued at approximately $17,021,850. The trade was a 4.22% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Daniel Joseph Apel sold 13,095 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Wednesday, April 22nd. The shares were sold at an average price of $71.35, for a total transaction of $934,328.25. Following the sale, the chief financial officer owned 162,905 shares of the company's stock, valued at approximately $11,623,271.75. The trade was a 7.44% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 33,095 shares of company stock valued at $2,326,228 over the last quarter. 3.60% of the stock is owned by company insiders. <h2>Trending Headlines about Arrowhead Pharmaceuticals</h2>Here are the key news stories impacting Arrowhead Pharmaceuticals this week:<ul> <li>Positive Sentiment: HC Wainwright reiterated a Buy rating and $100 price target on Arrowhead Pharmaceuticals, while raising estimates for FY2026 and Q4 2026 and lifting its Q4 2027 profit forecast. MarketBeat Arrowhead Pharmaceuticals report</li> <li>Positive Sentiment: Sanford C. Bernstein raised its price target from $35 to $46, signaling improved longer-term confidence in Arrowhead Pharmaceuticals even though the rating remains market perform. Benzinga report</li> <li>Positive Sentiment: Arrowhead’s recent strategic momentum, including its global license and collaboration agreement with Sarepta Therapeutics, continues to support investor optimism around the pipeline and partnership value. Business Wire article</li> <li>Neutral Sentiment: HC Wainwright made small, mixed EPS revisions across several quarters, with some periods nudged lower and others higher; the changes were modest and do not materially alter the overall bullish stance. MarketBeat Arrowhead Pharmaceuticals report</li> <li>Negative Sentiment: Bernstein’s new target of $46 is still well below Arrowhead’s recent trading level, implying meaningful downside if the stock rerates back toward that valuation. Benzinga report</li> </ul><h2>Arrowhead Pharmaceuticals Company Profile</h2> (Get Free Report)Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company's approach aims to offer durable, targeted treatments across a range of therapeutic areas. The company's pipeline includes multiple candidates in various stages of development.<h2>Recommended Stories</h2><ul><li>Five stocks we like better than Arrowhead Pharmaceuticals</li><li>Oklo Stock Could Be Ready for Another Massive Run</li><li>D-Wave Earnings Looked Weak, But Investors May Be Missing This</li><li>Nebius Upside Expands as AI Feedback Loop Intensifies</li><li>Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell</li></ul> <img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJXUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJXUg"/>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.<h2>Should You Invest $1,000 in Arrowhead Pharmaceuticals Right Now?</h2>Before you consider Arrowhead Pharmaceuticals, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arrowhead Pharmaceuticals wasn't on the list.While Arrowhead Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here </div>

ARWR

ARKG

HC Wainwright has revised its Q3 2026 earnings estimate for Arrowhead Pharmaceuticals (NASDAQ:ARWR), lowering it to ($1.03) per share from ($1.02). The firm maintains a "Buy" rating with a target price of $100. Other analysts have also adjusted their ratings and target prices, with a consensus rating of "Moderate Buy" and an average target of $87.80. Arrowhead's stock has seen fluctuations, currently priced at $77.88, with a market cap of $10.97 billion. The company reported a revenue of $73.74 million for the last quarter, down 86.4% year-over-year.

Market Beat

ArrowHead Pharma

Ark Genomic Revolution ETF

Invesco Biotechnology & Genome ETF

Invesco Nasdaq Biotechnology ETF

Direxion S&P Biotech Bull 3X

Proshares Ultra Nasdaq Biotech

ALPS Medical Breakthrough

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

VG Health

VanEck Biotech ETF

SPDR S&P Biotech

Health Care Select Sector SPDR

Morgan Stanley

ROYAL BANK OF CANADA

M&T Bank

Nordea Bank

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

M & T BANK CORP DEP SHS REPSTG 1/400TH INT PERP SER K

M & T BANK CORP PERP NON CUM PFD FIXED FLTG RATE SER H

M & T BANK CORP DEP SHS EA REP 1/400TH SHS SERIES J

What is HC Wainwright's Forecast for ARWR Q3 Earnings?